| Cat.No. | Name | Information |
|---|---|---|
| M9872 | BS3 (bis(sulfosuccinimidyl)suberate) | BS3 (bis(sulfosuccinimidyl)suberate) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| M41010 | PB038 | PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan. |
| M41009 | Val-Ala-PAB-MMAE | Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. |
| M41008 | Val-Ala-PABC-Exatecan | Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor). |
| M28881 | Mc-VC-PAB-SN38 | Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). |
| M28641 | Tesirine | Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity. |
| M28498 | Sulfo-PDBA-DM4 | Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. |
| M28205 | SGD-1910 | SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala. |
| M28111 | Lys-Nε-SPDB-DM4 | Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC). |
| M28031 | Mipsagargin | Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin. Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research. |
| M25312 | Zilovertamab vedotin | Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer. |
| M25138 | Pivekimab sunirine | Pivekimab sunirine (IMGN 632) is an antibody-drug conjugate (ADC) targeting CD123. Pivekimab sunirine comprises a high-affinity CD123 antibody, cleavable linker, and an indolinobenzodiazepine pseudodimer (IGN) payload. Pivekimab sunirine can be used for research of hematological malignancies. |
| M25118 | Farletuzumab ecteribulin | Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a drug-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. |
| M24944 | Serclutamab talirine | Serclutamab talirine (ABBV-321) is an EGFR-targeted antibody-drug conjugate (ADC). Serclutamab talirine is consisted of an antibody (AM-1-ABT-806) directed against activated EGFR and a pyrrolobenzodiazepine (PBD) dimer. Serclutamab talirine shows potent antitumor activity. |
| M24839 | Loncastuximab tesirine | Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma. |
| M24768 | Trastuzumab duocarmazine | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas. |
| M24536 | Moxetumomab pasudotox | Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
